LivaNova PLC (LIVN)
Fair bewertetFundamental
64
Kurs
$75.41
Marktkapitalisierung
$4.21B
Teil 1 · Was das Unternehmen wert ist
Übersicht
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19. September 2026 with claude-haiku-4-5 — shared with all users
Through its Maquet Cardiopulmonary unit, Getinge sells the heart-lung machines, oxygenators and ECMO circuits that LivaNova's Cardiopulmonary segment sells to the same hospital perfusion and cardiac-surgery departments worldwide.
Terumo's cardiovascular business supplies oxygenators, perfusion systems and disposables for open-heart surgery, overlapping directly with LivaNova's largest revenue line and competing for the same hospital tenders.
Medtronic competes on both of LivaNova's fronts — cardiopulmonary bypass equipment and disposables for cardiac surgery, and implantable neurostimulators used in drug-resistant epilepsy and difficult-to-treat neurological conditions.
NeuroPace's RNS responsive neurostimulation system targets the same drug-resistant focal epilepsy patients, and the same implanting epilepsy centres, that LivaNova's VNS Therapy depends on.
Haemonetics competes in the surgical blood-management products used in the same cardiac operating room, where LivaNova sells autotransfusion and blood-handling systems alongside its bypass equipment.
This privately held UK manufacturer sells perfusion monitoring and extracorporeal circuit systems to the same cardiac surgery units, and is named by LivaNova itself among its principal competitors.
Bilanz & Liquidität
Umsatz
$1.47B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$189M
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$173M
Gesamtes Eigenkapital
$1.20B
Gesamtverbindlichkeiten
$1.41B
Current Ratio
1.45
Zinsdeckungsgrad
5.43
Schulden/EBITDA
1.34
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$67.01
Aktueller Kurs
$75.41
Sicherheitsmarge
-12.5%
Innerer-Wert-Spanne
$48.94 - $85.07
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
22.57
ROE
-20.2%
P/B-Verhältnis
3.18
P/FCF
28.42
Bruttomarge
68.1%
ROIC
7.7%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
7.7%
WACC
9.7%
ROIC − WACC
-2.0 pp
Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.
Fundamentalanalyse-Kriterien
Bestanden (18)
- Price CAGR 5.55%
- ROIC 7.7%
- Gross Margin 68.1%
- P/FCF 28.42
- Debt/Equity ratio
- Operating Margin 12.7%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 15.4%
- Revenue Growth 5Y 8.2%
- Analyst Consensus 81% Buy
- Earnings Surprise avg 10.3%
- Earnings Quality (OCF/NI) 1.32
- Share Dilution -0.0%
- Net Margin Trend 12.8% vs -16.1%
Nicht bestanden (7)
- EPS shows upward trend
- P/B Ratio 3.18
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Piotroski F-Score 4/9
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Gemischte Signale: Einige Bereiche bedürfen Aufmerksamkeit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Institutionelle Beteiligungen
Für dieses Unternehmen liegen keine institutionellen Meldungen vor.
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Vladimir A. Makatsaria | CEO & Director | 52 |
| Mr. Alex Shvartsburg C.M.A. | Chief Financial Officer | 55 |
| Ms. Natalia Sergeyevna Kozmina | Chief Human Resources Officer | 54 |
| Mr. Ahmet Tezel Ph.D. | Chief Innovation Officer | 50 |
| Ms. Lindsey Little | VP & Chief Accounting Officer | - |
| Briana Gotlin | Vice President of Investor Relations | - |
| Ms. Anne M. Liddy | Chief Legal Officer | 49 |
| Deanna Wilke | Vice President of Corporate Communications | - |
| Mr. Philip Kowalczyk | Chief Strategy & Corporate Development Officer | - |
| Mr. Paul R. Buckman | President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement | 69 |
Prüfungsrisiko
9
Vorstandsrisiko
3
Vergütungsrisiko
2
Aktionärsrechterisiko
2
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-25
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-08-05
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-08-05
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for LIVN, sourced from Markets Gazette.
- 2/25/2026NEUTRALLivaNova (LIVN) Q4 2025 Earnings Call Transcript
The transcript of LivaNova PLC's Q4 2025 earnings conference call is now available, providing investors with a critical opportunity to delve into the company's financial performance and future outlook. While the specific content has not been disclosed, analysts and shareholders will be scrutinizing management's statements regarding revenues, profit margins, product pipeline, and guidance for the current fiscal year. This data is essential for assessing LivaNova's operational health and anticipating potential stock movements, thereby influencing both short-term and long-term investment strategies.
via Markets Gazette